MedTrace Logo

A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the Elderly

NCT04701788 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 331

Last updated 2022-02-16

No results posted yet for this study

Summary

To evaluate the the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine revaccinations in the elderly

Conditions

  • Vaccination

Interventions

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

The study group and the control group were injected with a dose of 23-valent pneumococcal polysaccharide vaccine. One month later, blood was collected and serum was separated.

Sponsors & Collaborators

  • Sichuan Center for Disease Control and Prevention

    collaborator OTHER_GOV

  • China National Biotec Group Company Limited

    lead INDUSTRY

Principal Investigators

  • Qianli Ma · Sichuan Center for Disease Control and Prevention

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-30
Primary Completion
2021-12-20
Completion
2022-02-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04701788 on ClinicalTrials.gov